Clorox Climbs and Could Clean Up Even More in the Months Ahead

Trading volume in the disinfectant maker's shares has been very active since February, which coincides with rising coronavirus fears.

We're All Rooting for Gilead Sciences in This Venture

I'm long GILD, but the fact is that the firm is not trying to make money off of Remdesivir at this point.

2 Picks, 2 Pans Among Small-Cap Biotechs Laboring in the Covid-19 Fields

Quotient Limited and Redhill Biopharma could deliver for shareholders, while Novavax Inc. and Inovio Pharmaceuticals may not in the end.

Wait for it: Centene Could Break Out to New Highs

Overall the charts of CNC are constructive but I would still want to buy strength.

Small-Caps Roar, Bets Against the Market, Trading Nvidia

Money movers are not buying protection for individual names, but they are starting to bet against the market en masse, while the Russell 2000 ran up 4% on Monday.

These Stocks and Sectors Should Hold Up Well Despite Covid-19

It is worth tracking these three names.

The Charts of UnitedHealth Group Remain Bullish, Buy a Dip to the $271 Area

Overall the charts and indicators of UNH are constructive.

Let's Talk About Getting Back in Business

The economy and society suffer each day we stay closed, so let's look at the data on the Covid-19 crisis as well as on the economy to see what could be next.

2 Sectors That Look Attractive Here: Technology and Healthcare

The charts of the XLK and the XLV are impressive.

Gilead Surges on Remdesivir Report: How to Play the Stock Now

We have a new price target for GILD.